Developer docs
API playgroundTry for free, no card

Search company profiles

Every Cure

Full company profile

uuid0000c1e

Namestring
Every Cure
Legal namestring
Every Cure, Inc.
Websiteurl
everycure.org
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Every Cure is a 501(c)(3) nonprofit organization founded in September 2022 and headquartered in Philadelphia, Pennsylvania, with the mission of systematically identifying and advancing drug repurposing opportunities to treat diseases lacking approved or adequate therapies. The organization was co-founded by Dr. David Fajgenbaum, a physician-scientist who saved his own life by repurposing sirolimus for idiopathic multicentric Castleman disease and has since advanced 14 repurposed treatments across Castleman disease, angiosarcoma, DADA2 syndrome, and other rare conditions; Dr. Grant Mitchell, formerly of McKinsey/QuantumBlack; and Tracey Sikora, who brings a decade of rare disease drug repurposing experience. Every Cure targets a defined unmet need: more than 300 million people globally have diseases without FDA-approved treatment, and only ~4,000 of ~18,000 recognized diseases have any approved therapy at all, leaving commercial drug developers with little financial incentive to pursue new uses for off-patent molecules.

The organization's core offering is an AI-powered computational pharmacophenomics platform (also referred to as MATRIX) that combines three approaches: a knowledge graph integrating over 100 biomedical datasets covering drug mechanisms, gene interactions, and disease pathways; LLM-based agentic workflows that emulate clinical reasoning chains; and real-world evidence models trained on prescription and medical record data. The platform ranks potential drug-disease matches and currently evaluates 66 million possible pairings across 3,000 approved drugs and 22,000 diseases within days. Every Cure complements this platform with an active pipeline of 10 drug repurposing programs organized into Frontier Explorers (laboratory studies), Clinical Gems (clinical studies), and Unsung Heroes (patient access programs), plus the ROADMAP Project published in JAMA Network Open, which provides a framework for rare disease organizations to pursue their own repurposing efforts.

Every Cure generates no commercial revenue; instead, it is funded by philanthropic donations, foundation grants, and government contracts. Cumulative fundraising reached approximately $110 million by October 2024, anchored by a $48.3 million three-year contract from ARPA-H (with up to $76 million announced for Phase 2) and a five-year $60 million commitment from TED's Audacious Project, alongside foundational grants from the Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and Arnold Ventures. Distribution of Every Cure's outputs occurs through academic publications (NEJM, Lancet, Blood), inclusion in clinical guidelines (UpToDate, NCCN), partnerships with patient organizations and CROs (Worldwide Clinical Trials), medical conference dissemination, and open-source data releases. The organization does not sell products or services; its "customers" are patients with rare and undertreated diseases, whose outcomes (documented remissions, hospice-to-recovery case studies) function as the organization's impact metrics.

Short descriptiontext

Every Cure is a Philadelphia-based nonprofit using an AI-powered computational pharmacophenomics platform to systematically identify and clinically advance repurposed uses of approved drugs, serving patients with the ~14,000 recognized diseases that lack FDA-approved treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug repurposing, computational pharmacophenomics, biomedical knowledge graph, rare disease treatment, open-source drug database
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
AI Drug Repurposing Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Philanthropic Donations
TypeGrants Donations
Description

Every Cure is a nonprofit organization that relies on donations from individuals, foundations, and corporate giving programs. Donations can be made through their website and are tax-deductible under Section 501(c)(3) of the Internal Revenue Code (EIN: 92-0240717).

everycure.org
2Government Grants
TypeGrants Donations
Description

The organization receives significant government funding including a $48.3 million contract from ARPA-H and is pursuing additional federal funding to support its AI platform development and clinical research programs.

prnewswire.com
3Corporate and Foundation Partnerships
TypeOthers
Description

Funding from strategic philanthropists including TED's Audacious Project ($60M commitment over 5 years), Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and others.

everycure.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Every Cure operates an AI-powered computational pharmacophenomics platform that systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and rank the highest-potential drug repurposing opportunities, generating efficacy scores for 66 million drug-disease matches within days. The organization takes end-to-end responsibility from AI-based identification through laboratory validation, clinical studies, and patient access programs for diseases lacking approved or affordable treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First patient treated with AI-identified drug (adalimumab for Castleman disease) achieved remission after being headed to hospice
+3 more records
Product overview1 text field

Every Cure operates as a nonprofit biotech organization that offers an integrated AI-powered drug repurposing ecosystem. The core offering is the Computational Pharmacophenomics AI Platform (also called MATRIX), which systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and prioritize drug repurposing opportunities. This platform is complemented by the ROADMAP Project, which provides guidance tools for rare disease organizations, and the company's Pipeline/Portfolio of active drug repurposing programs. The organization takes end-to-end responsibility from AI identification through clinical validation to patient access.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Collaboration on Bachmann-Bupp Syndrome (BABS) and repurposing of DFMO/eflornithine to ensure no patient goes undiagnosed and to advance treatment access.

2Conscience
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Partnership to advance drug repurposing initiatives, combining resources to expand reach and impact in identifying treatments for underserved diseases.

everycure.org
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-13
Description

Expanded collaboration leveraging Google Cloud's infrastructure and AI technologies including Gemini 2.0 to accelerate drug repurposing discoveries and improve patient outcomes.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-30
Description

Deployed BioPhy's artificial intelligence platform to accelerate drug repurposing efforts, enhance computational drug development, and enable clinical trial simulation capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-08
Description

Leveraging Atropos Health's GENEVA OS and Evidence Network to enable real-world data confirmation of drug repurposing opportunities and trial emulation capabilities to speed clinical development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-11
Description

Partnership with leading global full-service contract research organization (CRO) to accelerate discovery of treatments for rare disease patients through clinical trial support.

7Castleman Disease Collaborative Network (CDCN)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded by Dr. Fajgenbaum in 2012, CDCN is a key partner in advancing treatments for Castleman disease and related conditions through patient-driven initiatives.

everycure.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner institution led by Dr. Fajgenbaum where foundational drug repurposing research was conducted, including the sirolimus discovery for Castleman disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AI-for-drug-discovery and clinical-research platform using real-world patient data and federated learning to accelerate therapeutics development; overlaps with Every Cure in using real-world evidence and AI for drug-disease matching and trial design.

TypeEmerging player
Description

AI-driven oncology platform (RADR) that identifies responders and repurposes compounds for cancer indications; an emerging peer applying AI to drug-repurposing selection and trial design in a focused therapeutic area.

TypeDirect peer
Description

AI-native drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics; comparable to Every Cure as a data-and-AI-driven approach to expanding the druggable space, though focused on de novo discovery rather than repurposing.

4BPGbio
TypeDirect peer
Description

AI-driven biology and drug-repurposing company with an oncology-led pipeline of repurposed and novel compounds; comparable in pairing a Bayesian/AI discovery platform with a focus on repurposing for diseases with high unmet need.

TypeDirect peer
Description

AI-driven drug repurposing company focused specifically on rare diseases, combining knowledge graphs with patient and disease data to identify treatments; the closest peer to Every Cure in combining AI repurposing with a rare-disease mission.

TypeDirect peer
Description

Knowledge-graph-based AI platform for drug discovery and repurposing, including systematic identification of new indications for existing drugs; among the closest direct competitors in AI-enabled drug repurposing.

TypeDirect peer
Description

AI-driven precision medicine company using patient-derived data and active-learning platforms to accelerate small-molecule drug design; comparable to Every Cure in using AI to systematically map drug–disease relationships and prioritize candidates.

TypeDirect peer
Description

Applies generative AI and deep learning to identify novel drug targets and molecules across multiple therapeutic areas; a directly comparable AI-driven drug-discovery platform with similar knowledge-graph and predictive-modeling methodologies.

TypeDirect peer
Description

Uses AI (structure-based small-molecule design and screening) to discover and advance novel and repurposed therapeutics, partnering with pharma on pipeline programs; comparable in applying AI to systematically evaluate large drug–disease spaces.

10Castleman Disease Collaborative Network (CDCN)
TypeOthers
Description

Patient-organization partner co-founded by Dr. Fajgenbaum in 2012 and a key ecosystem collaborator for Every Cure; not a competitor but the closest peer-organization in disease-advocacy-driven drug repurposing for rare conditions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Every Cure

AI Drug Repurposing Platformeverycure.org

Every Cure is a Philadelphia-based nonprofit using an AI-powered computational pharmacophenomics platform to systematically identify and clinically advance repurposed uses of approved drugs, serving patients with the ~14,000 recognized diseases that lack FDA-approved treatments.

What Every Cure does

Every Cure is a 501(c)(3) nonprofit organization founded in September 2022 and headquartered in Philadelphia, Pennsylvania, with the mission of systematically identifying and advancing drug repurposing opportunities to treat diseases lacking approved or adequate therapies. The organization was co-founded by Dr. David Fajgenbaum, a physician-scientist who saved his own life by repurposing sirolimus for idiopathic multicentric Castleman disease and has since advanced 14 repurposed treatments across Castleman disease, angiosarcoma, DADA2 syndrome, and other rare conditions; Dr. Grant Mitchell, formerly of McKinsey/QuantumBlack; and Tracey Sikora, who brings a decade of rare disease drug repurposing experience. Every Cure targets a defined unmet need: more than 300 million people globally have diseases without FDA-approved treatment, and only ~4,000 of ~18,000 recognized diseases have any approved therapy at all, leaving commercial drug developers with little financial incentive to pursue new uses for off-patent molecules.

The organization's core offering is an AI-powered computational pharmacophenomics platform (also referred to as MATRIX) that combines three approaches: a knowledge graph integrating over 100 biomedical datasets covering drug mechanisms, gene interactions, and disease pathways; LLM-based agentic workflows that emulate clinical reasoning chains; and real-world evidence models trained on prescription and medical record data. The platform ranks potential drug-disease matches and currently evaluates 66 million possible pairings across 3,000 approved drugs and 22,000 diseases within days. Every Cure complements this platform with an active pipeline of 10 drug repurposing programs organized into Frontier Explorers (laboratory studies), Clinical Gems (clinical studies), and Unsung Heroes (patient access programs), plus the ROADMAP Project published in JAMA Network Open, which provides a framework for rare disease organizations to pursue their own repurposing efforts.

Every Cure generates no commercial revenue; instead, it is funded by philanthropic donations, foundation grants, and government contracts. Cumulative fundraising reached approximately $110 million by October 2024, anchored by a $48.3 million three-year contract from ARPA-H (with up to $76 million announced for Phase 2) and a five-year $60 million commitment from TED's Audacious Project, alongside foundational grants from the Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and Arnold Ventures. Distribution of Every Cure's outputs occurs through academic publications (NEJM, Lancet, Blood), inclusion in clinical guidelines (UpToDate, NCCN), partnerships with patient organizations and CROs (Worldwide Clinical Trials), medical conference dissemination, and open-source data releases. The organization does not sell products or services; its "customers" are patients with rare and undertreated diseases, whose outcomes (documented remissions, hospice-to-recovery case studies) function as the organization's impact metrics.

Every Cure firmographics

Firmographics
Name
Every Cure
Legal name
Every Cure, Inc.
Website
https://everycure.org
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Every Cure is a Philadelphia-based nonprofit using an AI-powered computational pharmacophenomics platform to systematically identify and clinically advance repurposed uses of approved drugs, serving patients with the ~14,000 recognized diseases that lack FDA-approved treatments.
Ownership category
akta.pro rank

Every Cure industry classification

Industry
Product category
AI Drug Repurposing Platform
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics

Keywords

  • AI drug repurposing
  • Computational pharmacophenomics
  • Biomedical knowledge graph
  • Rare disease treatment
  • Open-source drug database

Where Every Cure is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Every Cure business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Philanthropic Donations: Every Cure is a nonprofit organization that relies on donations from individuals, foundations, and corporate giving programs. Donations can be made through their website and are tax-deductible under Section 501(c)(3) of the Internal Revenue Code (EIN: 92-0240717).
  2. Government Grants: The organization receives significant government funding including a $48.3 million contract from ARPA-H and is pursuing additional federal funding to support its AI platform development and clinical research programs.
  3. Corporate and Foundation Partnerships: Funding from strategic philanthropists including TED's Audacious Project ($60M commitment over 5 years), Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, Elevate Prize Foundation, and others.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Every Cure product offering

Product offering

Core offering

Every Cure operates an AI-powered computational pharmacophenomics platform that systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and rank the highest-potential drug repurposing opportunities, generating efficacy scores for 66 million drug-disease matches within days. The organization takes end-to-end responsibility from AI-based identification through laboratory validation, clinical studies, and patient access programs for diseases lacking approved or affordable treatments.

Product overview

Every Cure operates as a nonprofit biotech organization that offers an integrated AI-powered drug repurposing ecosystem. The core offering is the Computational Pharmacophenomics AI Platform (also called MATRIX), which systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and prioritize drug repurposing opportunities. This platform is complemented by the ROADMAP Project, which provides guidance tools for rare disease organizations, and the company's Pipeline/Portfolio of active drug repurposing programs. The organization takes end-to-end responsibility from AI identification through clinical validation to patient access.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • First patient treated with AI-identified drug (adalimumab for Castleman disease) achieved remission after being headed to hospice
  • +3 more outcomes

Companies that use Every Cure

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Every Cure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature4 records

Every Cure partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Corewell Health and Michigan State UniversitycoreStrategic or Co-development Partner · 9 January 2026Collaboration on Bachmann-Bupp Syndrome (BABS) and repurposing of DFMO/eflornithine to ensure no patient goes undiagnosed and to advance treatment access.
  • ConscienceminorStrategic or Co-development Partner · 25 November 2025Partnership to advance drug repurposing initiatives, combining resources to expand reach and impact in identifying treatments for underserved diseases.
  • Google CloudcoreTechnology or Integration · 13 January 2025Expanded collaboration leveraging Google Cloud's infrastructure and AI technologies including Gemini 2.0 to accelerate drug repurposing discoveries and improve patient outcomes.
  • BioPhycoreTechnology or Integration · 30 April 2024Deployed BioPhy's artificial intelligence platform to accelerate drug repurposing efforts, enhance computational drug development, and enable clinical trial simulation capabilities.
  • Atropos HealthcoreTechnology or Integration · 8 January 2024Leveraging Atropos Health's GENEVA OS and Evidence Network to enable real-world data confirmation of drug repurposing opportunities and trial emulation capabilities to speed clinical development.
  • Worldwide Clinical TrialscoreStrategic or Co-development Partner · 11 May 2023Partnership with leading global full-service contract research organization (CRO) to accelerate discovery of treatments for rare disease patients through clinical trial support.
  • Castleman Disease Collaborative Network (CDCN)coreStrategic or Co-development PartnerCo-founded by Dr. Fajgenbaum in 2012, CDCN is a key partner in advancing treatments for Castleman disease and related conditions through patient-driven initiatives.
  • University of Pennsylvania - Center for Cytokine Storm Treatment & LaboratorycoreStrategic or Co-development PartnerAcademic partner institution led by Dr. Fajgenbaum where foundational drug repurposing research was conducted, including the sirolimus discovery for Castleman disease.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Every Cure competitors and assessment

Company assessment

Broad incumbents

  • Owkin: AI-for-drug-discovery and clinical-research platform using real-world patient data and federated learning to accelerate therapeutics development; overlaps with Every Cure in using real-world evidence and AI for drug-disease matching and trial design.

Emerging players

  • Lantern Pharma: AI-driven oncology platform (RADR) that identifies responders and repurposes compounds for cancer indications; an emerging peer applying AI to drug-repurposing selection and trial design in a focused therapeutic area.

Direct peers

  • Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics; comparable to Every Cure as a data-and-AI-driven approach to expanding the druggable space, though focused on de novo discovery rather than repurposing.
  • BPGbio: AI-driven biology and drug-repurposing company with an oncology-led pipeline of repurposed and novel compounds; comparable in pairing a Bayesian/AI discovery platform with a focus on repurposing for diseases with high unmet need.
  • Healx: AI-driven drug repurposing company focused specifically on rare diseases, combining knowledge graphs with patient and disease data to identify treatments; the closest peer to Every Cure in combining AI repurposing with a rare-disease mission.
  • BenevolentAI: Knowledge-graph-based AI platform for drug discovery and repurposing, including systematic identification of new indications for existing drugs; among the closest direct competitors in AI-enabled drug repurposing.
  • Exscientia: AI-driven precision medicine company using patient-derived data and active-learning platforms to accelerate small-molecule drug design; comparable to Every Cure in using AI to systematically map drug–disease relationships and prioritize candidates.
  • Insilico Medicine: Applies generative AI and deep learning to identify novel drug targets and molecules across multiple therapeutic areas; a directly comparable AI-driven drug-discovery platform with similar knowledge-graph and predictive-modeling methodologies.
  • Atomwise: Uses AI (structure-based small-molecule design and screening) to discover and advance novel and repurposed therapeutics, partnering with pharma on pipeline programs; comparable in applying AI to systematically evaluate large drug–disease spaces.

Others

  • Castleman Disease Collaborative Network (CDCN): Patient-organization partner co-founded by Dr. Fajgenbaum in 2012 and a key ecosystem collaborator for Every Cure; not a competitor but the closest peer-organization in disease-advocacy-driven drug repurposing for rare conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Every Cure social profiles

Digital presence

Every Cure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Every Cure leadership team

Management profile

Number of profiles

Profiles12 records

Every Cure funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Every Cure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Every Cure

What does Every Cure do?

Every Cure operates an AI-powered computational pharmacophenomics platform that systematically scans across 3,000 approved drugs and 22,000 recognized diseases to identify and rank the highest-potential drug repurposing opportunities, generating efficacy scores for 66 million drug-disease matches within days. The organization takes end-to-end responsibility from AI-based identification through laboratory validation, clinical studies, and patient access programs for diseases lacking approved or affordable treatments.

Is Every Cure a public or private company?

Every Cure is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Every Cure founded?

Every Cure was founded in 2022. It employs 51 to 100 people.

Where is Every Cure based?

Every Cure is headquartered in Philadelphia, United States, in the North America region.

How does Every Cure make money?

Three revenue lines are on record. Philanthropic Donations are the primary driver. The others are government Grants and corporate and Foundation Partnerships.

Who are Every Cure's main competitors?

Owkin is listed as a broad incumbent. Lantern Pharma is listed as an emerging player. Direct peers are Recursion Pharmaceuticals, BPGbio, Healx, BenevolentAI, Exscientia, Insilico Medicine and Atomwise. Castleman Disease Collaborative Network (CDCN) is listed as an others.

Does Every Cure have an API?

No public API is recorded for Every Cure.

What industry is Every Cure in?

Every Cure's product category is AI Drug Repurposing Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogEvery Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall ShortEvery Cure and OpenEvidence announced a partnership to repurpose existing medicines for patients with no commercial incentive. The collaboration uses OpenEvidence's AI models and physician network to evaluate hypotheses, match patients to trials, and disseminate evidence. The partnership aims to accelerate access to repurposed treatments for rare and underserved diseases.CNBCEvery Cure’s drug repurposing strategy isn’t what you think, and it could change rare disease treatmentEvery Cure, a non-profit organization founded in late 2022, is using AI to identify new uses for existing drugs to treat rare diseases, operating under a disease-agnostic approach rather than targeting specific conditions. The organization has built a portfolio of 10 active drug repurposing programs with a goal of treating 15 to 25 diseases by 2030, leveraging technology that has cut traditional research timelines from 100 days to approximately 17 hours. Early results include successful treatment of five children with Bachmann-Bupp syndrome using a decades-old drug originally developed for African sleeping sickness, with all five children showing meaningful clinical improvement.MediaPost'The Gift of Green Bananas' Brings Hope During IllnessHealthcare marketing agency Real Chemistry, through its 21Grams creative group, partnered with nonprofit Every Cure to create a holiday video card titled 'A Gift of Green Bananas,' following a Japanese-American father and daughter whose ritual of gifting green bananas serves as a symbol of resilience during a family cancer diagnosis. The film was written and directed by Sarah Kambe Holland and draws from a Japanese cultural tradition where the fruit's ripening process represents hope and something to anticipate. This marks 21Grams' second notable creative project of the year, following its Cannes Gold Lion win for Biogen's branded pharma campaign.MediaPostYuengling Brews New Creative Partner: RPAReal Chemistry's 21Grams group, in partnership with Every Cure, created a holiday video card titled "A Gift of Green Bananas" which tells the story of a Japanese-American father and daughter navigating a family cancer diagnosis. The film emphasizes themes of resilience and cultural connection amid illness, and has received positive feedback for its emotional impact. This initiative builds on the unique notion of green bananas representing hope in Japanese culture.GlobeNewswirePredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsPredictive Oncology and Every Cure announced a strategic collaboration to identify and prioritize drugs for repurposing in cancer treatment. Predictive Oncology's AI platform predicts tumor drug response with 92% accuracy, while Every Cure uses AI to match FDA-approved drugs to diseases. The partnership aims to accelerate repurposing efforts for patients with exhausted treatment options.GlobeNewswirePredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsPredictive Oncology and Every Cure announced a strategic collaboration to identify and prioritize drugs for repurposing in cancer treatment. Predictive Oncology's AI platform predicts tumor response with 92% accuracy, while Every Cure uses AI to match FDA-approved drugs to diseases. The partnership aims to accelerate repurposing efforts for patients with exhausted treatment options.Stock TitanPredictive Oncology Partners with Every Cure for AI-Driven Drug RepurposingPredictive Oncology and Every Cure announced a strategic collaboration to identify and prioritize drugs for repurposing in cancer treatment. The partnership leverages Predictive Oncology's AI platform and Every Cure's AI models to accelerate drug repurposing, aiming to deliver treatments in months rather than decades.YahooPredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsPredictive Oncology Inc. and Every Cure have announced a strategic collaboration aimed at identifying and prioritizing existing drugs for repurposing to improve cancer patient outcomes. This partnership utilizes Predictive Oncology's AI platform and Every Cure's commitment to treating diseases with no approved treatments, with the goal of accelerating the delivery of effective medications to patients. This collaboration is set to leverage both organizations' data and technology to enhance drug repurposing efforts.Predictive-OncologyPredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsPredictive Oncology Inc. and Every Cure announced a strategic collaboration to utilize AI-driven platforms for identifying and validating new indications for existing FDA-approved drugs. The partnership aims to accelerate drug repurposing efforts by leveraging Predictive Oncology's tumor sample biobank and machine learning capabilities alongside Every Cure's data models to treat patients with diseases lacking approved therapies.The New York TimesLos médicos le dijeron que iba a morir, pero la IA le salvó la vidaJoseph Coates, a 37-year-old man with a rare blood disorder, was told he would die but was saved by an AI model developed by David Fajgenbaum that repurposed existing drugs. The treatment put him in remission, and Every Cure, Fajgenbaum's nonprofit, has raised over $100 million to fund clinical trials of repurposed drugs.